<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576407</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00009955</org_study_id>
    <secondary_id>2R01AI047040-11A2</secondary_id>
    <secondary_id>R56 Bridge R01AI4704011A1</secondary_id>
    <secondary_id>5K12HD043494-09</secondary_id>
    <secondary_id>R01AI047040</secondary_id>
    <secondary_id>3R56AI047040-11A1S1</secondary_id>
    <secondary_id>R01AI054843</secondary_id>
    <secondary_id>#668</secondary_id>
    <nct_id>NCT00576407</nct_id>
  </id_info>
  <brief_title>Thymus Transplantation in DiGeorge Syndrome #668</brief_title>
  <official_title>Phase II Study of Thymus Transplantation in Complete DiGeorge Syndrome #668</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M. Louise Markert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Enzyvant Therapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to determine whether thymus transplantation without immunosuppression is
      effective in treating typical complete DiGeorge syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no safe and effective treatment for DiGeorge syndrome and most patients die by the
      age of two. Complete DiGeorge syndrome is characterized by very low T cell or very low na√Øve
      T cell numbers. In this study, typical complete DiGeorge syndrome subjects received human
      postnatal cultured thymus tissue transplants. Thymus tissue that would otherwise be discarded
      was transplanted into DiGeorge subjects in the operating room. At the time of
      transplantation, a skin biopsy was obtained to look for any preexisting T cells. After
      transplantation, subjects were followed by routine research immune evaluations, using blood
      samples obtained every 2-4 weeks. At approximately 2-3 months post-transplantation subjects
      underwent an open biopsy of the allograft. The biopsy was done under general anesthesia in
      the operating room. At the time of the graft biopsy, another skin biopsy was obtained to look
      for clonal populations of T cells.

      The protocol aims include: assessing thymopoiesis in the allograft biopsy; assessing
      immunoreconstitution of complete DiGeorge syndrome subjects after postnatal allogeneic thymus
      transplantation; assessing minimally invasive methods of assessing thymopoiesis (flow
      cytometry and polymerase chain reaction (PCR); assessing pre-transplant T cells which do not
      proliferate in response to mitogens (focusing on NK-T cells); and, assessing thymus
      transplantation safety and toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate at one year post-transplantation.</measure>
    <time_frame>One year post-transplantation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cell proliferative response to tetanus toxoid</measure>
    <time_frame>Approximately 1 year after transplantation</time_frame>
    <description>Proliferative response that is 10 fold over background</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>DiGeorge Syndrome</condition>
  <condition>Complete Typical DiGeorge Anomaly</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymus Tissue for Transplantation in Complete DiGeorge Syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymus Tissue for Transplantation</intervention_name>
    <description>Thymus transplantation is done using allogeneic cultured postnatal tissue from unrelated donors. Thymus tissue, the donor, &amp; donor's mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were transplanted into the recipient's quadriceps. Dose is number of grams of transplanted tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of transplantation, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-transplant allograft biopsy to evaluate for thymopoiesis &amp; graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-transplant, subjects followed by routine research immune evaluations, using blood samples for 2 years.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Thymus Tissue</other_name>
    <other_name>Thymus Tissue Transplantation</other_name>
    <other_name>Thymus Transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of complete DiGeorge syndrome which is either: T cells with &lt; 50/mm3 with
             naive phenotype; or &lt; 5% CD3 + T cells with naive T cell phenotype.

          -  Diagnosis of typical DiGeorge syndrome phenotype: &lt; 50 T cells/cumm and very low
             proliferative responses to mitogens (e.g. &lt; 20 fold response to mitogen
             phytohemagglutinin).

          -  Proliferative response to PHA &lt; 20 fold above background or &lt; 5000 counts per
             minute(cpm), whichever is higher.

        {Note: Subjects with PHA responses 20 fold or more over background or &gt; 5,000 cpm,
        whichever is higher, may be enrolled in another thymus transplant protocol.}

          -  Must have heart disease; hypocalcemia requiring replacement; 22q11 or 10p13
             hemizygosity; CHARGE association; or must be child of diabetic mother and have
             abnormal ears.

        Exclusion Criteria:

          -  Those who do not meet inclusion criteria

          -  Atypical DiGeorge syndrome phenotype

          -  Rash indicating atypical DiGeorge syndrome phenotype.

        Transplant Exclusion:

          -  Heart surgery &lt;4 weeks pre-tx date

          -  Heart surgery anticipated w/in 3 months of proposed tx

          -  Rejection by surgeon or anesthesiologist as surgical candidates

          -  Lack of sufficient muscle tissue to accept 0.2 grams/kg transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Louise Markert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Pediatrics, Allergy &amp; Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Li B, Li J, Devlin BH, Markert ML. Thymic microenvironment reconstitution after postnatal human thymus transplantation. Clin Immunol. 2011 Sep;140(3):244-59. doi: 10.1016/j.clim.2011.04.004. Epub 2011 Apr 16.</citation>
    <PMID>21565561</PMID>
  </reference>
  <reference>
    <citation>Chinn IK, Olson JA, Skinner MA, McCarthy EA, Gupton SE, Chen DF, Bonilla FA, Roberts RL, Kanariou MG, Devlin BH, Markert ML. Mechanisms of tolerance to parental parathyroid tissue when combined with human allogeneic thymus transplantation. J Allergy Clin Immunol. 2010 Oct;126(4):814-820.e8. doi: 10.1016/j.jaci.2010.07.016. Epub 2010 Sep 15.</citation>
    <PMID>20832849</PMID>
  </reference>
  <reference>
    <citation>Chinn IK, Milner JD, Scheinberg P, Douek DC, Markert ML. Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and FoxP3- T cells in complete DiGeorge anomaly. Clin Exp Immunol. 2013 Jul;173(1):140-9. doi: 10.1111/cei.12088.</citation>
    <PMID>23607606</PMID>
  </reference>
  <results_reference>
    <citation>Markert ML, Sarzotti M, Ozaki DA, Sempowski GD, Rhein ME, Hale LP, Le Deist F, Alexieff MJ, Li J, Hauser ER, Haynes BF, Rice HE, Skinner MA, Mahaffey SM, Jaggers J, Stein LD, Mill MR. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood. 2003 Aug 1;102(3):1121-30. Epub 2003 Apr 17.</citation>
    <PMID>12702512</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, Chinn IK, Hale LP, Kepler TB, He M, Sarzotti M, Skinner MA, Rice HE, Hoehner JC. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood. 2007 May 15;109(10):4539-47. Epub 2007 Feb 6.</citation>
    <PMID>17284531</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin Immunol. 2010 May;135(2):236-46. doi: 10.1016/j.clim.2010.02.007. Epub 2010 Mar 16. Review.</citation>
    <PMID>20236866</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML and Devlin BH. Thymic reconstitution (in Rich RR, Shearer WT, Fleischer T, Schroeder HW, Weyand CM, Frew A, eds., Clinical Immunology 3rd edn., Elsevier, Edinburgh) p 1253-1262, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Chinn IK, Devlin BH, Li YJ, Markert ML. Long-term tolerance to allogeneic thymus transplants in complete DiGeorge anomaly. Clin Immunol. 2008 Mar;126(3):277-81. Epub 2007 Dec 26.</citation>
    <PMID>18155964</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Li J, Devlin BH, Hoehner JC, Rice HE, Skinner MA, Li YJ, Hale LP. Use of allograft biopsies to assess thymopoiesis after thymus transplantation. J Immunol. 2008 May 1;180(9):6354-64.</citation>
    <PMID>18424759</PMID>
  </results_reference>
  <results_reference>
    <citation>Hudson LL, Louise Markert M, Devlin BH, Haynes BF, Sempowski GD. Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. Semin Immunol. 2007 Oct;19(5):297-309. Epub 2007 Nov 26. Review.</citation>
    <PMID>18035553</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Chinn IK, McCarthy EA, Li YJ. Factors affecting success of thymus transplantation for complete DiGeorge anomaly. Am J Transplant. 2008 Aug;8(8):1729-36. doi: 10.1111/j.1600-6143.2008.02301.x. Epub 2008 Jun 28.</citation>
    <PMID>18557726</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Chinn IK, McCarthy EA. Thymus transplantation in complete DiGeorge anomaly. Immunol Res. 2009;44(1-3):61-70. doi: 10.1007/s12026-008-8082-5.</citation>
    <PMID>19066739</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Marques JG, Neven B, Devlin BH, McCarthy EA, Chinn IK, Albuquerque AS, Silva SL, Pignata C, de Saint Basile G, Victorino RM, Picard C, Debre M, Mahlaoui N, Fischer A, Sousa AE. First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases. Blood. 2011 Jan 13;117(2):688-96. doi: 10.1182/blood-2010-06-292490. Epub 2010 Oct 26.</citation>
    <PMID>20978268</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, McCarthy EA, Chinn IK, Hale LP. Thymus Transplantation in Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Eds Lavinin C, Moran CA, Morandi U, Schoenhuber R. Springer-Verlag Italia, Milan, 2008, pp 255-267.</citation>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <disposition_first_submitted>September 6, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 12, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 14, 2012</disposition_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>M. Louise Markert</investigator_full_name>
    <investigator_title>Associate Professor, Duke University Medical Center, Pediatric Allergy &amp; Immunology</investigator_title>
  </responsible_party>
  <keyword>Thymus Transplantation</keyword>
  <keyword>DiGeorge Syndrome</keyword>
  <keyword>Athymia</keyword>
  <keyword>Low T cell numbers</keyword>
  <keyword>Immunoreconstitution</keyword>
  <keyword>Primary immunodeficiency</keyword>
  <keyword>DiGeorge Anomaly</keyword>
  <keyword>Complete DiGeorge</keyword>
  <keyword>Typical DiGeorge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>DiGeorge Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

